What caused the ALNEV.PA stock drop today?

The sharp drop to **€0.0072** reflects stock-specific selling, thin liquidity, absence of recent earnings updates and high clinical and financing uncertainty rather than sector-wide news.

What is Meyka AI’s grade for ALNEV.PA stock and what does it mean?

Meyka AI rates ALNEV.PA **58.20/100 (C+, HOLD)**. The grade considers sector and benchmark comparison, financial growth, metrics and analyst signals. It is informational and not investment advice.

What price target and outlook does Meyka AI give for ALNEV.PA stock?

Meyka AI's forecast model projects a **€0.0100** 12‑month baseline target from **€0.0072** today, an implied upside of about **+38.89%**. Forecasts are model-based projections and not guarantees.

Which catalysts should investors watch for ALNEV.PA stock?

Monitor corporate press releases on clinical trials, financing or partnerships, cash-runway updates and any regulatory news. These events are the most likely to move the stock price materially.

EU Stocks

ALNEV.PA down 99.6% to €0.0072 on EURONEXT: check cash and trial risks

ByHuzaifa Zahoor January 15, 2026

ALNEV.PA stock fell 99.60% to €0.0072 on EURONEXT at market close on 14 Jan 2026, making it one of today’s top losers. Trading volume surged to 4,152,238 shares, more than double the average of 1,597,803, as investors reacted to extremely thin market capitalisation and long-dated clinical risk. The move follows no actionable earnings update since 2019, leaving fundamentals and cash runway as the primary drivers of price action.